238 related articles for article (PubMed ID: 17063713)
1. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.
Alvarez FJ; Kisseberth WC; Gallant SL; Couto CG
J Vet Intern Med; 2006; 20(5):1178-83. PubMed ID: 17063713
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
Parsons-Doherty M; Poirier VJ; Monteith G
Can Vet J; 2014 Feb; 55(2):175-80. PubMed ID: 24489398
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.
Smallwood K; Tanis JB; Grant IA; Blackwood L; Killick DR; Amores-Fuster I; Elliott J; Mas A; Harper A; Marrington M; Finotello R
Vet Comp Oncol; 2019 Jun; 17(2):165-173. PubMed ID: 30666777
[TBL] [Abstract][Full Text] [Related]
4. A dexamethasone, melphalan, actinomycin-D and cytarabine chemotherapy protocol as a rescue treatment for feline lymphoma.
Elliott J; Finotello R
Vet Comp Oncol; 2018 Mar; 16(1):E144-E151. PubMed ID: 29044884
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).
Gillem J; Giuffrida M; Krick E
Vet Comp Oncol; 2017 Jun; 15(2):400-410. PubMed ID: 26463827
[TBL] [Abstract][Full Text] [Related]
6. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).
Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE
J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031
[TBL] [Abstract][Full Text] [Related]
7. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.
Hosoya K; Kisseberth WC; Lord LK; Alvarez FJ; Lara-Garcia A; Kosarek CE; London CA; Couto CG
J Vet Intern Med; 2007; 21(6):1355-63. PubMed ID: 18196747
[TBL] [Abstract][Full Text] [Related]
8. Combination of Bleomycin and Cytosine Arabinoside Chemotherapy for Relapsed Canine Lymphoma.
Batschinski K; Dervisis N; Kitchell B; Newman R; Erfourth T
J Am Anim Hosp Assoc; 2018; 54(3):150-155. PubMed ID: 29558212
[TBL] [Abstract][Full Text] [Related]
9. Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs.
Back AR; Schleis SE; Smrkovski OA; Lee J; Smith AN; Phillips JC
Vet Comp Oncol; 2015 Dec; 13(4):398-408. PubMed ID: 23910023
[TBL] [Abstract][Full Text] [Related]
10. Oral melphalan for the treatment of relapsed canine lymphoma.
Mastromauro ML; Suter SE; Hauck ML; Hess PR
Vet Comp Oncol; 2018 Mar; 16(1):E123-E129. PubMed ID: 28941072
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.
Siedlecki CT; Kass PH; Jakubiak MJ; Dank G; Lyons J; Kent MS
Can Vet J; 2006 Jan; 47(1):52-9. PubMed ID: 16536229
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of combination chemotherapy with dexamethasone for lymphoma in dogs.
Greenberg CB; Boria PA; Borgatti-Jeffreys A; Raskin RE; Lucroy MD
J Am Anim Hosp Assoc; 2007; 43(1):27-32. PubMed ID: 17209082
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine.
Van Vechten M; Helfand SC; Jeglum KA
J Vet Intern Med; 1990; 4(4):187-91. PubMed ID: 2401965
[TBL] [Abstract][Full Text] [Related]
17. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000).
Rassnick KM; Mauldin GE; Al-Sarraf R; Mauldin GN; Moore AS; Mooney SC
J Vet Intern Med; 2002; 16(5):576-80. PubMed ID: 12322709
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
19. Cytosine arabinoside as a single agent for the induction of remission in canine lymphoma.
Ruslander D; Moore AS; Gliatto JM; L'Heureux D; Cotter SM
J Vet Intern Med; 1994; 8(4):299-301. PubMed ID: 7983628
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs.
Rassnick KM; Moore AS; Collister KE; Northrup NC; Kristal O; Chretin JD; Bailey DB
J Vet Intern Med; 2009; 23(2):317-22. PubMed ID: 19192147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
